Search results for "emission"

showing 10 items of 2441 documents

A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-i…

2010

Abstract OBJECTIVE: To evaluate the efficacy of 1-year maintenance after a 6-week cycle of early intravesical chemotherapy, as the role of maintenance in intravesical chemotherapy is debated. PATIENTS AND METHODS: Between May 2002 and August 2003, 577 patients with non-muscle-invasive bladder cancer (NMI-BC) underwent transurethral resection (TUR) and early intravesical chemotherapy (epirubicin, 80 mg/50 mL). They were randomized between a 6-week induction cycle and the induction cycle plus maintenance with 10 monthly instillations. In all, 95 patients with T1G3, Tis or single and primary Ta-T1 G1-G2 tumours were excluded; 482 patients at intermediate risk of recurrence continued the study.…

AdultAged 80 and overMaleAntibiotics AntineoplasticRemission InductionCystoscopyintravesical chemotherapy bladder carcinomaMiddle AgedCombined Modality TherapySettore MED/24 - UrologiaAdministration IntravesicalTreatment OutcomeUrinary Bladder NeoplasmsHumansFemaleNeoplasm Recurrence LocalEpidemiologic MethodsAgedEpirubicin
researchProduct

Usefulness of N-terminal pro-B-type natriuretic peptide levels in predicting residual myocardial ischemia in patients with ST elevation acute myocard…

2007

N-terminal pro-b-type natriuretic peptide (NT pro-BNP) is a neurohormone synthesized predominantly in ventricular myocardium. In patients with symptoms of heart failure, elevation in NT pro-BNP accurately identifies ventricular dysfunction. However, NT pro-BNP levels are not specific for ventricular dysfunction in patients who do not have overt symptoms of heart failure, suggesting that other cardiac processes such as myocardial ischemia may also cause elevation in NT pro-BNP. The study was aimed to determine whether NT pro-BNP elevations are associated with myocardial ischemia.One hundred and thirty patients (104 males, 26 females, mean age 61+12 years), with ST elevation acute myocardial …

AdultAged 80 and overMaleTomography Emission-Computed Single-PhotonMyocardial InfarctionMyocardial IschemiaOrganotechnetium CompoundsMiddle AgedSensitivity and SpecificityPeptide FragmentsElectrocardiographyLogistic ModelsOrganophosphorus CompoundsROC CurvePredictive Value of TestsNatriuretic Peptide BrainExercise TestOdds RatioHumansFemaleRadiopharmaceuticalsBiomarkersAgedEchocardiography StressRetrospective Studies
researchProduct

PET Studies of Net Blood—Brain Clearance of FDOPA to Human Brain: Age-Dependent Decline of [18F]Fluorodopamine Storage Capacity

2005

Conventional methods for the graphical analysis of 6-[18F]fluorodopa (FDOPA)/positron emission tomography (PET) recordings ( Kappin) may be prone to negative bias because of oversubtraction of the precursor pool in the region of interest, and because of diffusion of decarboxylated FDOPA metabolites from the brain. These effects may reduce the sensitivity of FDOPA/PET for the detection of age-related changes in dopamine innervations. To test for these biasing effects, we have used a constrained compartmental analysis to calculate the brain concentrations of the plasma metabolite 3- O-methyl-FDOPA (OMFD) during 120 mins of FDOPA circulation in healthy young, healthy elderly, and Parkinson's …

AdultAgingFluorine Radioisotopesmedicine.medical_specialtyMetaboliteDiffusionCentral nervous system diseasechemistry.chemical_compoundDopamineInternal medicinemedicineHumans18F-fluorodopamineFluorodopamedicine.diagnostic_testbusiness.industryPutamenBrainHuman brainMiddle Agedmedicine.diseaseDihydroxyphenylalanineEndocrinologymedicine.anatomical_structureNeurologychemistryPositron emission tomographyPositron-Emission TomographyNeurology (clinical)Cardiology and Cardiovascular MedicineNuclear medicinebusinessmedicine.drugJournal of Cerebral Blood Flow & Metabolism
researchProduct

Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease.

2008

1. Aliment Pharmacol Ther. 2008 Jun;27(12):1210-23. Epub 2008 Mar 14. Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease. Tinè F, Rossi F, Sferrazza A, Orlando A, Mocciaro F, Scimeca D, Olivo M, Cottone M. Divisione di Gastroenterologia, Azienda Ospedaliera V. Cervello, Palermo, Italy. fabiotinemd@virgilio.it BACKGROUND: Remission and response are the main outcomes to evaluate the efficacy of new treatments for Crohn's disease (CD). AIM: To explain variation of remission and response rates in active luminal CD. METHODS: We studied control patients from trials of biological therapies through articles retriev…

AdultBiological TherapyMalePlacebosTreatment Outcomemetanalysis. biologics.crohn's diseaseCrohn DiseaseDose-Response Relationship DrugRemission InductionHumansFemaleRandomized Controlled Trials as Topic
researchProduct

Early administration of an immunomodulator and induction of remission in insulin-dependent diabetes mellitus

1990

A clinical trial was undertaken to determine whether intensive thymopentin administration enhances remission of insulin-dependent diabetes (IDDM) during the first year after diagnosis. Dosage with insulin was minimized with target control of blood glucose levels less than or equal to 7.8 mmol/l before meals. Remission was defined as a prolonged period after IDDM onset (not less than 3 months) characterized by a non-insulin-receiving (NIR) state in which target metabolic control was reached without administration of insulin and with a valid C-peptide response, evaluated after standard breakfast. Sixteen IDDM patients aged 12-31 years, recruited within 2 weeks of initiation of insulin therapy…

AdultBlood Glucosemedicine.medical_specialtyAdolescentmedicine.medical_treatmentImmunologyGastroenterologyInternal medicineDiabetes mellitusmedicineHumansInsulinImmunology and AllergyThymopentinChildGlycemicImmunity CellularC-Peptidebusiness.industryInsulinRemission InductionHemoglobin AReceptors Interleukin-2medicine.diseaseClinical trialTiterDiabetes Mellitus Type 1EndocrinologyChild PreschoolInsulin dependent diabetesMetabolic control analysisThymopentinbusinessmedicine.drugJournal of Autoimmunity
researchProduct

Visual-motion suppression in congenital pendular nystagmus.

2009

Patients with a congenital pendular nystagmus are known not to experience oscillopsia in a normal visual environment. The data of a 31-year-old female patient suffering from a congenital pendular nystagmus are presented. The aim of the fluorodeoxyglucose positron emission tomography (FDG-PET) experiment was to analyze the regional cerebral glucose metabolism (rCGM) during minimal as well as maximal nystagmus. Video-oculography showed a maximum in frequency of the horizontal pendular nystagmus during gaze to the left, whereas the zone of minimal nystagmus was 10 degrees to the right. Two sessions with an 18F-fluorodeoxyglucose tracer were performed to analyze cerebral blood-glucose utilizati…

AdultBlood Glucosemedicine.medical_specialtygenetic structuresVisual AcuityNystagmusAudiologyGeneral Biochemistry Genetics and Molecular BiologyPendular nystagmusOscillopsiaHistory and Philosophy of ScienceFluorodeoxyglucose F18medicineHumansGeneral NeuroscienceGazeMagnetic Resonance Imagingeye diseasesVisual motionFunctional imagingVisual cortexmedicine.anatomical_structurePositron-Emission TomographyFemalemedicine.symptomPsychologyNystagmus CongenitalHorizontal pendular nystagmusAnnals of the New York Academy of Sciences
researchProduct

Thalamic infarctions cause side-specific suppression of vestibular cortex activations.

2005

H2O15-PET was performed during caloric vestibular stimulation of the right and left external ears in eight right-handed patients with acute unilateral infarctions or haemorrhages of the posterolateral thalamus (four right, four left). The posterolateral thalamus is the relay station for ipsi- and contralateral ascending vestibular input to the multiple multisensory vestibular cortex areas. The aim of this study was to evaluate the differential effects of unilateral vestibular thalamic lesions on thalamo-cortical projections, right hemispheric dominance and reciprocal inhibitory visual-vestibular interaction, as well as perceptual and ocular motor consequences during caloric irrigation. The …

AdultBrain InfarctionMaleEye MovementsThalamusMotion PerceptionSensory systemVestibular nucleiThalamusCortex (anatomy)otorhinolaryngologic diseasesmedicineCaloric TestsImage Processing Computer-AssistedPsychophysicsHumansInner earDominance CerebralAgedVestibular systemCerebral CortexBrain MappingAnatomyMiddle AgedVestibular cortexElectrooculographymedicine.anatomical_structureVestibulePositron-Emission TomographyFemalesense organsNeurology (clinical)Vestibule LabyrinthPsychologyNeuroscienceBrain : a journal of neurology
researchProduct

Relapse Analysis of Irradiated Patients Within the HD15 Trial of the German Hodgkin Study Group

2015

Purpose To determine, in the setting of advanced-stage of Hodgkin lymphoma (HL), whether relapses occur in the irradiated planning target volume and whether the definition of local radiation therapy (RT) used by the German Hodgkin Study Group (GHSG) is adequate, because there is no harmonization of field and volume definitions among the large cooperative groups in the treatment of advanced-stage HL. Methods and Materials All patients with residual disease of ≥2.5 cm after multiagent chemotherapy (CTX) were evaluated using additional positron emission tomography (PET), and those with a PET-positive result were irradiated with 30 Gy to the site of residual disease. We re-evaluated all sites o…

AdultCancer ResearchNeoplasm Residualmedicine.medical_treatmentPlanning target volumeIrradiated VolumeBleomycinFluorodeoxyglucose F18RecurrenceGermanyAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineCooperative groupRadiology Nuclear Medicine and imagingRadiation treatment planningCyclophosphamideEtoposideChemotherapyRadiationmedicine.diagnostic_testbusiness.industryRadiotherapy Planning Computer-AssistedRadiotherapy DosageMiddle AgedCombined Modality TherapyHodgkin DiseaseRadiation therapyOncologyDoxorubicinVincristinePositron emission tomographyPositron-Emission TomographyProcarbazinePrednisoneHodgkin lymphomaRadiopharmaceuticalsbusinessNuclear medicineInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Inflammatory Pseudotumor of Mediastinum Treated with Tomotherapy and Monitored with FDG-PET/CT: Case Report and Literature Review

2010

Mediastinal inflammatory pseudotumor is a rare disease with reactive pseudoneoplastic features and a proven capacity for local invasion. The radiographic appearance of inflammatory pseudotumor is quite non-specific and the definitive diagnosis is based on the histological evaluation of tissue specimens. Resection of the lesion is the treatment of choice. However, nonsurgical treatments such as radiotherapy and steroids have been employed in the setting of incomplete surgical resection, tumor recurrence, and patients being unfit for surgery. The case described here is being reported because of the rare mediastinal location and atypical treatment approach including salvage irradiation and mon…

AdultCancer Researchmedicine.medical_specialtyPET/CTRadiographymedicine.medical_treatmenttomotherapyAdult; Granuloma Plasma Cell; Humans; Mediastinal Neoplasms; Positron-Emission Tomography; Tomography X-Ray Computed; Fluorodeoxyglucose F18; RadiopharmaceuticalsMediastinal NeoplasmsGranuloma Plasma CellTomotherapy030218 nuclear medicine & medical imagingInflammatory pseudotumorLesion03 medical and health sciences0302 clinical medicineFluorodeoxyglucose F18HumansMedicineTomographyPET-CTGranulomabusiness.industryMediastinumGeneral MedicinemediastinumX-Ray ComputedRadiation therapymedicine.anatomical_structureOncologyPositron-Emission TomographyPlasma CellInflammatory pseudotumorRadiologyRadiopharmaceuticalsmedicine.symptomTomography X-Ray Computedbusiness030217 neurology & neurosurgeryRare diseaseTumori Journal
researchProduct

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients…

2008

Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab to standard chemotherapy improves treatment outcome in LPL and the subgroup of LPL patients fulfilling the criteria of Waldenstroem's macroglobulinemia (WM). A total of 69 patients with previously untreated LPL were enrolled into the trial; 64 patients were evaluable for treatment outcome. In all, 48 of the 64 LPL patients fulfilled the criteria of WM. Patients were randomly assigned to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, n=34) or CHOP (n=30). R-CHOP resulted in significantly highe…

AdultCancer Researchmedicine.medical_specialtyVincristineCyclophosphamidemedicine.medical_treatmentCHOPGastroenterologyDisease-Free SurvivalLymphoplasmacytic LymphomaAntibodies Monoclonal Murine-Derived03 medical and health sciences0302 clinical medicineimmune system diseasesPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideAgedChemotherapybusiness.industryRemission InductionAntibodies MonoclonalHematologyMiddle Agedmedicine.disease3. Good healthLymphomaSurgeryTreatment OutcomeOncologyDoxorubicinVincristine030220 oncology & carcinogenesisPrednisoneRituximabWaldenstrom MacroglobulinemiaRituximabbusiness030215 immunologymedicine.drugLeukemia
researchProduct